Skip to content

ioMRI in the Surgery of Brain Metastases.

Evaluation of the Efficacy and Safety of Intraoperative MRI in the Surgery of Brain Metastases.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07197632
Acronym
MET-MRI
Enrollment
154
Registered
2025-09-29
Start date
2025-01-17
Completion date
2030-01-01
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastases

Keywords

ioMRI, Brain metastases, Neurosurgical resection

Brief summary

The study aims to improve the surgical treatment of brain metastases through the use of advanced imaging techniques. The investigators are examining how intraoperative MRI (iMRI) can aid surgeons in precisely locating and removing tumors, with the potential to enhance surgical outcomes and reduce the need for additional procedures. While iMRI offers the promise of better tumor visualization during surgery, it is also associated with longer surgical times and may carry the risk of increased complications. This study seeks to carefully evaluate these aspects to determine the overall benefits and challenges of iMRI in brain metastasis surgeries. The ultimate aim is to enhance treatment effectiveness and improve recovery and health outcomes for participants dealing with brain metastases.

Interventions

PROCEDURESurgery with intraoperative MRI

In this clinical study, we have the unique opportunity to utilize a 3 Tesla MRI intraoperatively during the surgical resection of brain metastases. This approach is distinctly different from standard procedures and offers several advantages. The use of a 3 Tesla MRI provides high-resolution imaging during surgery, offering unparalleled detail of brain structures and tumor boundaries. This level of imaging precision is typically not available in standard surgical procedures. Through real-time visualization, surgeons can better differentiate between tumor tissue and healthy brain tissue, potentially increasing the accuracy of tumor removal and minimizing damage to surrounding areas. Unlike conventional methods, this procedure allows for immediate intraoperative imaging feedback, enabling surgical teams to adjust their techniques dynamically

Sponsors

Technical University of Munich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients for whom surgical resection of brain metastasis is indicated

Exclusion criteria

* age \< 18 * 3T MRI contraindications

Design outcomes

Primary

MeasureTime frameDescription
Rate for complete resectionimmediately after the surgeryThe postoperative MRI obtained within 72 hours after surgery will be analyzed to identify the rates of resection.

Secondary

MeasureTime frameDescription
ComplicationsPerioperativelyHemorrhages, Ischemias, epileptic seizures, hydrocephalus, wound infection, Anesthesiological complications, neurological deficits

Countries

Germany

Contacts

CONTACTMaria Goldberg
maria.goldberg@tum.de+498941402151

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026